<DOC>
	<DOCNO>NCT02635880</DOCNO>
	<brief_summary>To evaluate safety efficacy investigational version Cutera enlightenTM laser offer multiple wavelength removal benign pigmented lesion .</brief_summary>
	<brief_title>A Clinical Evaluation Novel Multi-Wavelength Laser Benign Pigmented Lesion Removal</brief_title>
	<detailed_description>The purpose investigation evaluate safety efficacy investigational version Cutera enlightenTM laser benign pigment lesion ( BPL ) removal . Currently , enlightenTM laser offer two wavelength : 532nm KTP 1064nm Nd : YAG . The version laser investigation allow user choose range wavelength .</detailed_description>
	<mesh_term>Pigmentation Disorders</mesh_term>
	<criteria>Female Male , 18 65 year age ( inclusive ) . Fitzpatrick Skin Type I III ( Appendix 3 ) . Clinical diagnosis benign pigment lesion locate hand , body face . Presence 5 benign pigment lesion treatment area , range diameter 2 8 mm . Has use prescription overthecounter topical cream ( hydroquinone , retinoids corticosteroid ) designate treatment area within 4 week enrollment study willing refrain use duration study . Subject must able read , understand sign Informed Consent Form . Must willing able adhere treatment followup schedule posttreatment care instruction . Wiling cover treat area limit sun exposure use approve sunscreen SPF 50 high treat area start 2 4 week treatment every day duration study , include followup period . Willing digital photograph take treatment area agree use photograph presentation , educational marketing purpose . Agree undergo procedure ( ) treatment BPL study . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study , plan become pregnant duration study . Participation clinical trial another device drug within 6 month prior enrollment study . Any type prior cosmetic treatment target area within 6 month study participation , chemical peel , laser lightbased procedure , surgery . Presence premalignant malignant lesion treatment area ( , limit pigment actinic keratosis , lentigo maligna lentigo maligna melanoma ) history premalignant malignant lesion treatment area . Shows sign actinic bronze and/or excessively tan area treat , unable unlikely refrain tan study ( example , subject 's occupation require regular sun exposure ) . Skin abnormalities target area , e.g. , cut , scrape , wound , scar , large mole . Pregnant and/or breastfeeding . Having infection , dermatitis rash treatment area . Significant concurrent illness , diabetes mellitus cardiovascular disease , e.g. , uncontrolled hypertension . Suffering coagulation disorder take prescription anticoagulation medication . History keloid scarring , hypertrophic scar abnormal wound healing . History immunosuppression/immune deficiency disorder currently use immunosuppressive medication . History vitiligo , eczema , psoriasis . History connective tissue disease , systemic lupus erythematosus scleroderma . History seizure disorder due light . Any use medication know increase sensitivity light accord Investigator 's discretion . History disease stimulate heat , recurrent herpes simplex and/or herpes zoster ( shingle ) treatment area , unless treatment conduct follow prophylactic regimen History radiation treatment area undergo systemic chemotherapy treatment cancer . History pigmentary disorder , particularly tendency hyper hypopigmentation . Systemic use corticosteroid isotretinoin within 12 month study participation . Anytime life , use gold therapy ( gold salt ) disorder rheumatologic disease lupus . Current smoker history smoking within 6 month study participation . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>